The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Subscribe To Our Newsletter & Stay Updated
